If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
=== TCI Bangladesh Limited === TCI Bangladesh delivers integrated, single window logistics and supply chain solutions. Headquartered in Dhaka, it operates across critical transit points, Petrapole, Benapole and Chittagong Port, to serve a growing clientele.
February 23, 2011 Venezuela Economists expressed concern with regards to Venezuela's economy improving due to instability in the private sector pressured by the socialist government, as José Guerra, former manager at the Central Bank of Venezuela, stated that private investment, accounting for half of Venezuela's GDP, dropped 2.2% in 2010.
==== Relapsing-remitting multiple sclerosis ==== Many disease-modifying medications have been approved for RRMS; and some are highly effective at decreasing the number of attacks. Highly effective medications include monoclonal antibodies directed at CD20-expressing B cells (administred by injection or infusion, e.g. rituximab), natalizumab (an integrin) or alemtuzumab, which depletes white blood cells more broadly. Treatment of CIS with interferons decreases the chance of progressing to clinical MS. In general, aggressive treatment in the early stages of MS produces the best long-term outcomes. The relative effectiveness of different treatments is unclear, as most have only been compared to placebo or a small number of other therapies. There is high confidence that natalizumab, cladribine, or alemtuzumab are decreasing relapses over two years for people with RRMS. Natalizumab and interferon beta-1a (Rebif) may reduce relapses compared to both placebo and interferon beta-1a (Avonex) while Interferon beta-1b (Betaseron), glatiramer acetate, and mitoxantrone may also prevent relapses. There is moderate confidence that a two-year treatment with natalizumab slows disability progression for people with RRMS. All medications are associated with adverse effects that may influence their risk-to-benefit profiles. Ublituximab was approved for medical use in the United States in December 2022.
Sources: en.wikipedia.org
==== 2009–2015 ==== The JWP published its report on elements 113–116 and 118 in 2011. It recognised the JINR–LLNL collaboration as having discovered elements 114 and 116, but did not accept either team's claim to element 113 and did not accept the JINR–LLNL claims to elements 115 and 118. The JINR–LLNL claim to elements 115 and 113 had been founded on chemical identification of their daughter dubnium, but the JWP objected that current theory could not distinguish between superheavy group 4 and group 5 elements by their chemical properties with enough confidence to allow this assignment. The decay properties of all the nuclei in the decay chain of element 115 had not been previously characterised before the JINR experiments, a situation which the JWP generally considers "troublesome, but not necessarily exclusive", and with the small number of atoms produced with neither known daughters nor cross-reactions the JWP considered that their criteria had not been fulfilled. The JWP did not accept the Riken team's claim either due to inconsistencies in the decay data, the small number of atoms of element 113 produced, and the lack of unambiguous anchors to known isotopes. In early 2009, the Riken team synthesised the decay product 266Bh directly in the 248Cm + 23Na reaction to establish its link with 278113 as a cross-bombardment. They also established the branched decay of 262Db, which sometimes underwent spontaneous fission and sometimes underwent the previously known alpha decay to 258Lr.
== Menu == Fridays has a large menu with an emphasis on alcoholic beverages. These drinks come in liquid as well as frozen form and TGI often runs specials or creates unique drinks based on seasonality and location. TGI Fridays formerly served Atkins-approved appetizers, entrées, and desserts. In 2006, the Atkins name was removed from the menu when Atkins filed for bankruptcy, but the restaurant continues to offer both low-carbohydrate and low-fat menu items. The UK and US menus offer gluten-free items.
=== Other environmental factors === Allergic diseases are more common in industrialized countries than in countries that are more traditional or agricultural, and there is a higher rate of allergic disease in urban populations versus rural populations, although these differences are becoming less defined. Historically, the trees planted in urban areas were predominantly male to prevent litter from seeds and fruits, but the high ratio of male trees causes high pollen counts, a phenomenon that horticulturist Tom Ogren has called "botanical sexism". Alterations in exposure to microorganisms is another plausible explanation, at present, for the increase in atopic allergy. Endotoxin exposure reduces release of inflammatory cytokines such as TNF-α, IFNγ, interleukin-10, and interleukin-12 from white blood cells (leukocytes) that circulate in the blood. Certain microbe-sensing proteins, known as Toll-like receptors, found on the surface of cells in the body, are also thought to be involved in these processes.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.